ES2177942T3 - Formulacion farmaceutica de liberacion prolongada conteniendo mizolastina. - Google Patents

Formulacion farmaceutica de liberacion prolongada conteniendo mizolastina.

Info

Publication number
ES2177942T3
ES2177942T3 ES97907145T ES97907145T ES2177942T3 ES 2177942 T3 ES2177942 T3 ES 2177942T3 ES 97907145 T ES97907145 T ES 97907145T ES 97907145 T ES97907145 T ES 97907145T ES 2177942 T3 ES2177942 T3 ES 2177942T3
Authority
ES
Spain
Prior art keywords
prolonged release
pharmaceutical formulation
mizolastine
release containing
containing mizolastine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97907145T
Other languages
English (en)
Inventor
Maryvonne Chariot
Gareth Lewis
Jean Montel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Application granted granted Critical
Publication of ES2177942T3 publication Critical patent/ES2177942T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

FORMULACION FARMACEUTICA DE LIBERACION PROLONGADA QUE CONTIENE MIZOLASTINA, CARACTERIZADA PORQUE LLEVA UN NUCLEO FORMADO POR UN COMPRIMIDO DE LIBERACION PROLONGADA QUE LLEVA MIZOLASTINA ASOCIADO A UNA MATRIZ GRASA Y A UN ACIDO ORGANICO, ESTANDO DICHO COMPRIMIDO REVESTIDO.
ES97907145T 1996-03-04 1997-02-28 Formulacion farmaceutica de liberacion prolongada conteniendo mizolastina. Expired - Lifetime ES2177942T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9602662A FR2745500B1 (fr) 1996-03-04 1996-03-04 Formulations pharmaceutiques a liberation prolongee contenant de la mizolastine

Publications (1)

Publication Number Publication Date
ES2177942T3 true ES2177942T3 (es) 2002-12-16

Family

ID=9489799

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97907145T Expired - Lifetime ES2177942T3 (es) 1996-03-04 1997-02-28 Formulacion farmaceutica de liberacion prolongada conteniendo mizolastina.

Country Status (34)

Country Link
US (2) US6165507A (es)
EP (1) EP0906101B1 (es)
JP (2) JP2000512617A (es)
KR (1) KR100369888B1 (es)
CN (1) CN1112929C (es)
AR (1) AR006082A1 (es)
AT (1) ATE219365T1 (es)
AU (1) AU725494B2 (es)
BG (1) BG63451B1 (es)
BR (1) BR9707827A (es)
CA (1) CA2247405C (es)
CO (1) CO4780020A1 (es)
CY (1) CY2293B1 (es)
CZ (1) CZ291418B6 (es)
DE (1) DE69713505T2 (es)
DK (1) DK0906101T3 (es)
EE (1) EE03511B1 (es)
ES (1) ES2177942T3 (es)
FR (1) FR2745500B1 (es)
HU (1) HU227472B1 (es)
IL (1) IL126050A (es)
IN (1) IN187739B (es)
NO (1) NO315841B1 (es)
NZ (1) NZ331947A (es)
OA (1) OA10854A (es)
PL (1) PL189813B1 (es)
PT (1) PT906101E (es)
RU (1) RU2173997C2 (es)
SK (1) SK282112B6 (es)
TR (1) TR199801574T2 (es)
TW (1) TW491711B (es)
UA (1) UA49004C2 (es)
WO (1) WO1997032584A1 (es)
ZA (1) ZA971830B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10101564A (ja) * 1996-09-27 1998-04-21 Mitsubishi Chem Corp 鼻炎予防及び／又は治療剤
JP2002087960A (ja) * 2000-07-14 2002-03-27 Toyama Chem Co Ltd 徐放性錠剤
EP1322158B1 (en) * 2000-10-02 2012-08-08 USV Ltd. Sustained release pharmaceutical compositions containing metformin and method of their production
US7052706B2 (en) 2001-06-08 2006-05-30 Nostrum Pharmaceuticals, Inc. Control release formulation containing a hydrophobic material as the sustained release agent
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
WO2004078164A1 (en) * 2003-03-04 2004-09-16 Nostrum Pharmaceuticals, Inc. Control release formulation containing a hydrophobic material as the sustained release agent
DE10337697A1 (de) * 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
WO2010013823A2 (en) 2008-07-28 2010-02-04 Takeda Pharmaceutical Company Limited Pharmaceutical composition
JP5744412B2 (ja) * 2010-03-26 2015-07-08 テバ製薬株式会社 フロセミド製剤
US20140179712A1 (en) 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4364945A (en) * 1979-12-13 1982-12-21 Whittle Barry J Nasal composition for relieving nasal distress
US4421736A (en) * 1982-05-20 1983-12-20 Merrel Dow Pharmaceuticals Inc. Sustained release diethylpropion compositions
US4590062A (en) * 1984-04-16 1986-05-20 Tech Trade Corp. Dry direct compression compositions for controlled release dosage forms
FR2587029B1 (fr) * 1985-09-11 1987-10-30 Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
JPH0776172B2 (ja) * 1986-04-16 1995-08-16 藤沢薬品工業株式会社 マトリツクス錠
JPS62283926A (ja) * 1986-06-02 1987-12-09 Nippon Chemiphar Co Ltd 塩酸ニカルジピン持続性組成物
JPS63141967A (ja) * 1986-11-21 1988-06-14 エイ・エッチ・ロビンス・カンパニー・インコーポレーテッド 抗アレルギー薬として有用な１−アリールオキシー４−［（４−アリール）−１−ピペラジニル］−２−ブタノール
DE3812799A1 (de) * 1988-04-16 1989-10-26 Sanol Arznei Schwarz Gmbh Oral zu verabreichende pharmazeutische zubereitung mit kontrollierter wirkstofffreisetzung und verfahren zu deren herstellung
JP3195391B2 (ja) * 1991-11-14 2001-08-06 エスエス製薬株式会社 徐放性トラピジル錠
RU2015975C1 (ru) * 1992-02-13 1994-07-15 Пятигорский фармацевтический институт Производные 4-оксо-1,4-дигидропиримидина, обладающие антиаллергической и иммунотропной активностью
US5686105A (en) * 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
IT1264696B1 (it) * 1993-07-09 1996-10-04 Applied Pharma Res Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata
JPH07112932A (ja) * 1993-08-27 1995-05-02 Mitsui Toatsu Chem Inc 徐放性医薬製剤

Also Published As

Publication number Publication date
NO984035D0 (no) 1998-09-02
JP2000512617A (ja) 2000-09-26
AR006082A1 (es) 1999-08-11
SK121098A3 (en) 1999-01-11
AU1930097A (en) 1997-09-22
CZ291418B6 (cs) 2003-03-12
RU2173997C2 (ru) 2001-09-27
DK0906101T3 (da) 2002-10-14
CO4780020A1 (es) 1999-05-26
CZ279198A3 (cs) 1999-01-13
US6165507A (en) 2000-12-26
AU725494B2 (en) 2000-10-12
KR100369888B1 (ko) 2003-05-17
OA10854A (fr) 2003-02-05
WO1997032584A1 (fr) 1997-09-12
BR9707827A (pt) 1999-07-27
DE69713505T2 (de) 2003-02-13
PL328763A1 (en) 1999-02-15
NO984035L (no) 1998-10-22
EP0906101B1 (fr) 2002-06-19
HK1017999A1 (en) 1999-12-10
CN1112929C (zh) 2003-07-02
PL189813B1 (pl) 2005-09-30
BG63451B1 (bg) 2002-02-28
SK282112B6 (sk) 2001-11-06
HUP9902458A2 (hu) 2000-05-28
HU227472B1 (en) 2011-07-28
FR2745500B1 (fr) 1998-04-03
IL126050A0 (en) 1999-05-09
JP2007182451A (ja) 2007-07-19
TR199801574T2 (xx) 1998-11-23
EE03511B1 (et) 2001-10-15
KR19990087387A (ko) 1999-12-27
UA49004C2 (uk) 2002-09-16
CN1212624A (zh) 1999-03-31
US20050202089A1 (en) 2005-09-15
HUP9902458A3 (en) 2002-11-28
CA2247405C (en) 2004-04-20
ZA971830B (en) 1997-09-04
FR2745500A1 (fr) 1997-09-05
BG102692A (en) 1999-04-30
CY2293B1 (en) 2003-07-04
IL126050A (en) 2004-05-12
TW491711B (en) 2002-06-21
PT906101E (pt) 2002-09-30
ATE219365T1 (de) 2002-07-15
EE9800275A (et) 1999-02-15
CA2247405A1 (en) 1997-09-12
DE69713505D1 (de) 2002-07-25
NO315841B1 (no) 2003-11-03
IN187739B (es) 2002-06-15
NZ331947A (en) 2000-03-27
EP0906101A1 (fr) 1999-04-07

Similar Documents

Publication Publication Date Title
ES2165115T3 (es) Un procedimiento para la purificacion de fosfatidinilserina.
ES2148345T3 (es) Composicion farmaceutica con ciclosporina a, un derivado de vitamina e y un emulsionante.
AU2001266703A1 (en) Uniform active matrix oled displays
BR9911914B1 (pt) n-arilamidas do ácido sulfonilaminocarboxìlico substituìdas por enxofre, processo para sua preparação, bem como preparações farmacêuticas que compreendem as mesmas.
ES2113105T3 (es) Reactivos para uso en bioluminiscencia.
ES2164286T3 (es) Emplasto con sustancias activas.
AU3301799A (en) Light emitting diode dot matrix display system with audio output
AU2001272953A1 (en) System for obfuscating computer code to prevent disassembly
NO20020348L (no) Peptid acceptor ligeringsmetoder
ES2098140T3 (es) Liosferas que contienen gonadotropina.
NO20002826D0 (no) Hydroksamsyrederivater som matriksmetallprotease (MMO) - inhibitorer
ES2116094T3 (es) Sistema aglutinante con caracteristicas de auto-liberacion.
GB2380675A (en) Method of increased bioavailability of nutrients and pharmaceutical preparations with tetrahydropiperine and its analogues and derivatives
AR026968A1 (es) Una tableta matriz que permite la liberacion prolongada de trimetazidina lluego de su administracion por via oral
UY28134A1 (es) Formas de dosificación que comprenden un inhibidor de la ptec y un inhibidor de la hmg-coa- reductasa
AR025052A1 (es) Derivados de 2-dialquilaminoalquilbifenilo sustituidos, procedimiento para su preparacion, medicamentos que contienen estos compuestos y el uso de estoscompuestos para la preparacion de medicamentos.
AU2192400A (en) Readable matrix addressable display system
ES2170501T3 (es) Composicion farmaceutica antivirica que comprende acido glicirrizico y al menos una proteina que posee actividad antivirica.
CR6683A (es) Sistema de entrega de quelator de hierro
GB0117783D0 (en) Illumination method illumination system and the components thereof, especially for illuminating hollow bodies such as signs inscriptions letters especially r
IL129420A0 (en) Substituted 4-biphenyl-4-hydroxybutyric acid derivatives as matrix metalloprotease inhibitors
AR030662A1 (es) Beta-tio-alfa-aminoacidos, procedimiento para su fabricacion, medicamentos que contienen estos compuestos y el uso de los tioaminoacidos para la preparacion de medicamentos
AR006082A1 (es) Formulaciones farmacéuticas de liberación prolongada, que contienen mizolastina
ID17326A (id) Turunan-turunan asam 4-arilbutirat tersubstitusi sebagai inhibitor-inhibitor matriks metalloprotease
ES2082927T3 (es) Derivados de (p-carbonilaminofenil)-sulfonil-nitrometano.